Go Pro
→ Why This Small AI Company Holds 150 Patents (From Brownstone Research) (Ad)tc pixel Free LIPO Stock Alerts

Lipella Pharmaceuticals (LIPO) Competitors

Lipella Pharmaceuticals logo
$0.0005 0.00 (0.00%)
As of 09/18/2026 12:06 PM Eastern
Compare

LIPO vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy Lipella Pharmaceuticals stock or one of its competitors? Lipella Pharmaceuticals's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lipella Pharmaceuticals compare to Alvotech?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Alvotech has higher revenue and earnings than Lipella Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipella Pharmaceuticals$536.36K0.00-$5.02M-$2.42N/A
Alvotech$491.95MN/AN/AN/AN/A

In the previous week, Alvotech had 4 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 4 mentions for Alvotech and 0 mentions for Lipella Pharmaceuticals. Alvotech's average media sentiment score of 0.20 beat Lipella Pharmaceuticals' score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company Overall Sentiment
Lipella Pharmaceuticals Neutral
Alvotech Neutral

Alvotech has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Alvotech's return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lipella Pharmaceuticals-988.83% -224.08% -172.88%
Alvotech N/A N/A N/A

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Alvotech beats Lipella Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Apollomics?

Apollomics (NASDAQ:APLMW) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Apollomics has higher revenue and earnings than Lipella Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
Lipella Pharmaceuticals$536.36K0.00-$5.02M-$2.42N/A

In the previous week, Apollomics' average media sentiment score of 0.00 equaled Lipella Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Apollomics Neutral
Lipella Pharmaceuticals Neutral

Apollomics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Apollomics' return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Lipella Pharmaceuticals -988.83%-224.08%-172.88%

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Apollomics beats Lipella Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Aravive?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

In the previous week, Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
Lipella Pharmaceuticals Neutral
Aravive Neutral

Aravive has lower revenue, but higher earnings than Lipella Pharmaceuticals. Aravive is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipella Pharmaceuticals$536.36K0.00-$5.02M-$2.42N/A
AraviveN/AN/AN/A-$0.90N/A

Aravive has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Aravive's return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lipella Pharmaceuticals-988.83% -224.08% -172.88%
Aravive N/A N/A N/A

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 35.8% of Aravive shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by insiders. Comparatively, 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Aravive beats Lipella Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

In the previous week, bioAffinity Technologies had 1 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 1 mentions for bioAffinity Technologies and 0 mentions for Lipella Pharmaceuticals. Lipella Pharmaceuticals' average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.88 indicating that Lipella Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
bioAffinity Technologies Negative
Lipella Pharmaceuticals Neutral

bioAffinity Technologies has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. bioAffinity Technologies' return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
Lipella Pharmaceuticals -988.83%-224.08%-172.88%

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

bioAffinity Technologies has higher revenue and earnings than Lipella Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.85MN/AN/AN/AN/A
Lipella Pharmaceuticals$536.36K0.00-$5.02M-$2.42N/A

Summary

bioAffinity Technologies beats Lipella Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to BioVie?

Lipella Pharmaceuticals (NASDAQ:LIPO) and BioVie (NASDAQ:BIVIW) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

In the previous week, BioVie had 3 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 3 mentions for BioVie and 0 mentions for Lipella Pharmaceuticals. BioVie's average media sentiment score of 0.37 beat Lipella Pharmaceuticals' score of 0.00 indicating that BioVie is being referred to more favorably in the news media.

Company Overall Sentiment
Lipella Pharmaceuticals Neutral
BioVie Neutral

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioVie has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. BioVie's return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lipella Pharmaceuticals-988.83% -224.08% -172.88%
BioVie N/A N/A N/A

BioVie has lower revenue, but higher earnings than Lipella Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipella Pharmaceuticals$536.36K0.00-$5.02M-$2.42N/A
BioVieN/AN/AN/AN/AN/A

Summary

BioVie beats Lipella Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Get Lipella Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LIPO vs. The Competition

Export
MetricLipella PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2K$3.89B$7.24B$13.19B
Dividend YieldN/A3.64%2.57%12.81%
P/E Ratio0.0014.23275.4925.40
Price / Sales0.001,419.61646.0189.45
Price / CashN/A108.9076.2551.42
Price / Book0.0015.4510.466.33
Net Income-$5.02M-$22.86M$3.49B$358.33M
7 Day PerformanceN/A-1.21%0.59%1.12%
1 Month PerformanceN/A-3.29%-1.74%-2.39%
1 Year PerformanceN/A37.74%18.13%5.35%

Lipella Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LIPO
Lipella Pharmaceuticals
N/A$0.00
flat		N/A-99.9%$2K$536.36KN/A4
ALVOW
Alvotech
N/A$0.31
flat		N/A-66.1%$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
flat		N/A-39.3%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.22
+38.1%		N/A+296.0%$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LIPO) was last updated on 9/20/2026 by MarketBeat.com Staff.
From Our Partners
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...
American Alternative | Sponsoredtc pixel
“Elon’s nightmare” could fund your retirement
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
NVDA CEO says it’s a "once-in-a-generation opportunity"
NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...
Monument Traders Alliance | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel